Pfizer and the United States government have struck an agreement for Pfizer to producer millions of doses for its Covid-19 vaccine. Pfizer would deliver 100 million doses into the United States once the vaccine has been approved. CNBC’s “Squawk Box” crew discusses. For more coronavirus live updates: https://www.cnbc.com/2020/07/22/coronavirus-live-updates.html For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi
The vaccine would be free to Americans, according to the deal, though health care providers could charge to administer it.
Pfizer is working on the vaccine with BioNTech, a German company. Clinical trials began in April, and Pfizer announced positive early results this week, though it has yet to announce that data have been vetted and published in a medical journal. Larger safety and efficacy studies could begin later this month.
Pfizer Inc. and BioNTech SE are setting a price ceiling of less than $20 a dose that will impact how much other companies can charge to protect people from Covid-19.
Bloomberg reports that Pfizer’s $19.50 price-point takes into account the “public health requirements during the pandemic,” said Sally Beatty, a Pfizer spokeswoman. The companies are pursuing a two-dose regimen of one of its vaccine candidates, and the roughly $40 course, Beatty said, is “almost 30% less than what others charge for a seasonal flu vaccine.”
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.